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The cytotoxic effect of Aplidin was investigated on fresh leukaemia cells derived from children with B-cell-precursor (BCP) acute
lymphoblastic leukaemia (ALL) by using stromal-layer culture system and on four cell lines, ALL-PO, Reh, ALL/MIK and TOM-1,
derived from patients with ALL with different molecular genetic abnormalities. In ALL cell lines Aplidin was cytotoxic at nanomolar
concentrations. In the ALL cell lines the drug-induced cell death was clearly related to the induction of apoptosis and appeared to be
p53-independent. Only in ALL-PO 20nM Aplidin treatment caused a block of vascular endothelial growth factor (VEGF) secretion
and downregulation of VEGF-mRNA, but Aplidin cytotoxicity does not seem to be related to VEGF inhibition since the sensitivity of
ALL-PO cells to Aplidin is comparable to that observed for the other cells used. Aplidin induced a G1 and a G2M block in ALL cell
lines. In patient-derived leukaemia cells, Aplidin induced a strong cytotoxicity evidenced in a stroma-supported immunocytometric
assay. Cells from children with genetic abnormalities such as t(9;22) and t(4;11) translocations, associated with an inferior treatment
outcome, were sensitive to Aplidin to the same extent as that observed in other BCP-ALL cases. Aplidin exerted a strong cell killing
effect (488%) against primary culture cells from five relapsed ALL cases, at concentrations much lower than those reported to be
achieved in plasma of patients receiving Aplidin at recommended doses. Taken together these data suggest that Aplidin could be a
new anticancer drug to be investigated in ALL patients resistant to available therapy.
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Acute lymphoblastic leukaemia (ALL) is the most common form of
cancer in children. It arises in bone marrow from malignant B-
lymphoid progenitors. Among the distinguishing cellular features
of ALL, clonal abnormalities can be identified in approximately
65–70% of cases. Acute lymphoblastic leukaemia cells are sensitive
to several currently used drug treatments, but in approximately
one-third of the children, the disease recurs during, or following,
therapy (Pui, 2000; Pui et al, 2001). Therefore, the identification of
new antileukaemia drugs that are effective against ALL, particu-
larly following a relapse, may help further improvement of
treatment. Acute lymphoblastic leukaemia-derived primary cells
are being used to improve the sensitivity of in vitro methods to
measure new drug effectiveness–the goal of the work is presented
here.
Aplidin (dehydro-didemnin B) is a marine depsipeptide isolated
from the Mediterranean tunicate Aplidium albicans. It has shown
activity against both human haematological and solid tumour cell
lines growing in vitro (Urdiales et al, 1996; Lobo et al, 1997;
Depenbrock et al, 1998; Geldof et al, 1999), in vivo murine B16
melanoma and in several human tumours xenografts (Faircloth
et al, 1995, 1996).
Aplidin inhibits the progression of cells from G1 to the S phase
of the cell cycle (Crampton et al, 1984). Recently, a G2 block was
described for Aplidin in human leukaemia Molt-4 cell line (Erba
et al, 2002). Inhibition of protein synthesis via GTP-dependent
elongation factor 1-alpha in vitro (Crews et al, 1994), DNA and
RNA syntheses in different cell lines (Crampton et al, 1984; Sakai
et al, 1996) and inhibition of ornithine decarboxylase have been
reported for Didemnins as well as for Aplidin (Urdiales et al, 1996;
Erba et al, 2002).
In phase I and phase II clinical studies that are in progress, no
neutropenia but a moderate lymphopenia has been observed
(Raymond et al, 2000; Armand et al, 2001; Ciruelos Gil et al, 2002).
In this study, we assess the cytotoxic effect of Aplidin on fresh
leukaemia cells derived from children with B-cell-precursor (BCP)
ALL by using stromal-layer culture system, established by
Campana and co-workers (Manabe et al, 1992; Campana et al,
1993, 1999; Kumagai et al, 1996). Aplidin effectiveness was also
evaluated by assessing the cytotoxicity and the induction of
apoptosis in four human leukaemic cell lines, ALL-PO, Reh, ALL/
MIK and TOM-1, derived from patients with ALL with different
molecular genetic abnormalities.
MATERIALS AND METHODS
Cell lines
The leukaemic cell lines, Reh, ALL/MIK, TOM-1 (Rosenfeld et al,
1977; Okabe et al, 1987; Higa et al, 1994) and ALL-PO (Gobbi et al, Received 3 March 2003; revised 21 May 2003; accepted 22 May 2003
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s1997), were derived from BCP-ALL patients and are all char-
acterised by particular chromosomal translocations that are
representative of the molecular genetic abnormalities most
frequently found in childhood: two Philadelphia-positive cell lines
TOM-1 and ALL/MIK cells with a t(9;22), Reh cells with a t(12;21)
and ALL-PO cells with a t(4;11).
Cells were grown in an RPMI 1640 culture medium (Sigma-
Aldrich, St Louis, MI, USA) with 10% Hyclone FBS (Hyclone
Laboratories, Inc., Logan, UT, USA) and 4mM glutamine at 371Ci n
a humidified atmosphere containing 5% CO2 in T25cm
2 tissue
culture flasks (IWAKY, Bibby Sterilin, Staffordshire, UK).
Stroma-supported cultures of ALL cells
Leukaemic bone-marrow (BM) samples were collected from 14
patients with BCP-ALL aged less than 1–14 years (median, 6 years)
either at the time of diagnosis (nine patients) or at relapse (five
patients). The institutional review board approved this study and
informed consent was obtained from patients and their guardians.
In all cases, more than 80% of the blasts were positive for CD19,
class II antigens, terminal deoxynucleotidyl transferase (TdT), and
lacked surface immunoglobulins (sIg). Karyotype features were
determined by conventional banding techniques. Other clinical
features of the patients are listed in Table 1.
Mononuclear cells (MNC) were obtained by centrifugation on a
density gradient using Ficoll-Paque (Pharmacia LKB, Uppsala,
Sweden). After washing with phosphate-buffered saline (PBS) ALL
samples were cryopreserved in RPMI-1640 medium, with 50%
heat-inactivated FBS Hyclone and 10% dimethyl sulphoxide
(DMSO) and were stored in liquid nitrogen before use in the in
vitro studies.
Previously frozen leukaemic cells were cultured and only
cultures that had greater than 90% cell viability by trypan blue
dye exclusion were used.
Bone marrow stromal layers were prepared as previously
described by Campana and co-workers (Manabe et al, 1992;
Campana et al, 1993, 1999). Briefly, normal BM MNC were
resuspended in RPMI-1640 that contained 10% FCS, 1mM
hydrocortisone, 2mML -glutamine, and 1% penicillin–streptomy-
cin. Cells were incubated at 371Ci n5 %C O 2 and 90% humidity in
T2 5c m
2 tissue culture flasks (IWAKY) and were fed every 7 days
by replacing 50% of the supernatant with identical fresh medium.
After formation of confluent layers, cells were detached by
trypsin, washed once with RPMI-1640 with 10% FBS and
resuspended in fresh stroma culture medium. Cells were seeded
in 96-well flat-bottom plates at 3 10
4 cellswell
 1.
Drug treatment on cell lines
Aplidin was kindly supplied by PharmaMar SA (Madrid). The
effect of drug treatment on cell lines was evaluated by a standard
growth inhibition assay.
Leukaemia cells in the exponentially growing phase were treated
for 1h with different concentrations of Aplidin. After treatment,
cells were washed with PBS and incubated with fresh drug-free
medium; viable cells number was estimated by means of a Coulter
Counter (Beckman Coulter Corp., Hialeath, FL, USA) at different
time intervals after drug-washout.
Drug treatment on leukaemic BM cells
To determine the cytotoxicity of Aplidin in patient samples, we
first established the cells in culture. The media from the BM
stroma was removed and the adherent cells were washed seven
times with AIM-V serum-free tissue culture medium (Gibco BRL).
Resuspended leukaemia cells in AIM-V medium were aliquoted as
3 10
5 cells on the stromal layers. Blast cells from individual
patients were exposed for 7 days at 371Ci n5 %C O 2 and 90%
humidity to different Aplidin concentrations in log increments that
ranged from 0.005 to 5nM.
Cell cycle
Monoparametric DNA analysis Exponentially growing leukaemic
cells were treated for 1h with 0, 5, 10, and 20nM Aplidin. After
treatment, the drug-containing medium was removed, the cells
were washed with PBS and were placed in fresh medium. At
different time intervals after drug-washout, the number of cells was
evaluated by a Coulter Counter and the cells were fixed in 70%
ethanol and kept at 41C before DNA staining (Erba et al, 2002).
Biparametric BrdUrd/DNA analysis During the last 15min of
drug treatment, 20mM bromodeoxyuridine (BrdUrd) was added
to the cells. After treatment the drug-containing medium
was removed, the cells were washed twice with PBS and fresh
medium was provided. After 1h treatment and at different
time intervals after drug-washout, control and treated cells
were fixed in 70% ethanol and stored at 41C before staining.
With this protocol it was also possible to obtain a distinct
evaluation of cell cycle perturbations in cells which were in
Sphase (BrdUrd-positive cells), G1 phase or G2M phase (BrdUrd-
negative cells) during 1h 10nM Aplidin exposure (Erba et al,
2002).
Table 1 Clinical features of the patients
Case (no) Age (years) Sex WBC (l
 1) Phenotype DNA index Karyotype Follow-up
11 1 F 2 1  10
9 cALL 1,00 46,XX +8 CR
22 M 1 1  10
6 cALL 1,20 53, XY,+4,+6,+8,+12,+20+21+21+21 +8 CR
31 3 F 1 4  10
6 Pre-Pre-B-ALL 1,00 46,XX +5 CR
44 F 1 1  10
6 cALL 1,06 50,XX,+21[c] +5 CR
5 o1F 1 3  10
6 Pre-B-ALL 1,00 46,XX,+8,+19,+22 +4 CR
6 3 M 7,9 10
6 cALL 1,00 47,XY,del(14q21),+marker +5 CR
7 4 M 350 10
6 cALL 1,00 46,XY t (9;22) Resistant
81 0 F 2 7  10
6 cALL 1,21 58,XX,+ ,+1,+3,+8,+14,+16,+18,21,+19,+19,+21,+21,+21/46,XX +30 CR
9 9 M 140 10
6 Pre-pre-B ALL 1,00 46,XY t (4;11)/47,XY +38 CR
10
a F1 1  10
6 cALL ND ND Exitus
11
a 7M 1 3  10
6 Pre-B ALL 1,00 46, XY Exitus
12
a 5 F 132 10
6 LLA B mature 1,00 No mitosis +2 TMO
13
a 3M 5 8  10
9 cALL 1,00 ND Exitus
14
a 9M 3 5  10
9 Null ALL ND 46,XY Exitus
a¼relapse. ND¼not determined.
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sDetection of apoptosis and caspase-3 activation in ALL cell
lines
At different time intervals after drug-washout, the cells were fixed
in 70% ethanol for terminal-dUTP-transferase (TdT) or in 1%
paraformaldehyde for caspase analysis and stored at 41C. The fixed
cells were washed in cold PBS and incubated in 50ml of TdT and
FITC-conjugated dUTP deoxynucleotides solution (Roche Diag-
nostic SpA, Milan, Italy) or PE-conjugated rabbit anti-active
caspase-3 (Becton Dickinson, San Jose ´, CA, USA) and analysed by
flow cytometry (Erba et al, 2002).
Assessment of cytotoxicity and apoptosis on leukaemic BM
cells
Before and after culturing on stroma, the ALL cell recovery and
phenotype were determined as previously described (Manabe et al,
1992; Campana et al, 1993). Briefly, at termination of the cultures,
cells were passed through a 19-gauge needle to disrupt clumps
formed by stromal cells, washed with PBS that contained 0.2%
bovine serum albumin and 0.2% sodium azide (PBSA) and
incubated with Leu-12-PE (anti-CD19, Becton Dickinson, San Jose,
CA, USA). After two washes in PBSA, the cells were resuspended in
0.5% paraformaldehyde and counted using a FACScan instrument
and Cell Quest software (Becton Dickinson). Using the light-scatter
dot plot, which depicts cell size and granularity, we identified the
area where the vast majority of viable leukaemia cells were located
at the beginning of cultures. This area was delimited with an
electronic gate, which subsequently was used to enumerate
leukaemia cells at the end of culture. The number of nonapoptotic
lymphoid cells detected within a 30-s interval was corrected for the
percentage of CD19þ cells present. The cell counts of drug-treated
and control samples were compared to calculate the percentage of
viable cells that remained after drug treatment. The following
formula was used to calculate relative cell recovery after drug
treatment: (no. cells recovered with drug)/(no. of cells recovered
without drug) 100.
VEGF RNAse protection
Exponentially growing cells were treated for 1h with Aplidin
(20nM) and total RNA purified with the TRIZOL reagent (Gibco
BRL) at 1, 6 and 24h after drug-washout. VEGF and VEGFR-
1mRNA were measured by RNase protection assay using a
commercially available kit (Becton Dickinson).
ELISA assay
The assay, aimed at evaluating the concentration of VEGF-A in the
medium of cells, was performed on 96-well plates coated with an
anti-VEGF antibody (Quantikine kit, R&D Systems Europe, Oxon,
UK). Standards of VEGF protein ranging from 1000 to 31.2pgml
 1
were prepared after reconstituting VEGF standard with 1ml of
calibrator diluent. To each well, 50ml of Assay Diluent and 200mlo f
medium (or standard) were added; after 2h of incubation, wells
were washed three times with wash buffer and 200ml of VEGF-
conjugated were added. After 2h, wells were washed three times
and 200ml of Substrate Solution was added. After 20min, 50mlo f
stop solution was added to each well and optical density was
evaluated by means of a plate-reader spectrophotometer (Labsys-
tem Multiskan, Dasit, Italy) at 540nm.
Liquid chromatography–tandem mass spectrometry
analysis
Liquid chromatography–tandem mass spectrometry (LC–MS/MS)
analyses of Aplidin in medium were performed using a method
similar to that described for rat plasma (Celli et al, 1999).
RESULTS
Cytotoxicity, apoptosis and cell cycle perturbations
induced by Aplidin on ALL cell lines
Figure 1A shows the growth inhibitory effect of 1h treatment with
different concentrations of Aplidin on different cell lines. Aplidin
was active at nanomolar concentrations in all the cell lines and the
cytotoxic effect was dose dependent. An irreversible growth
inhibitory effect was observed after 1h using 10nM Aplidin
treatment in All-PO, ALL/MIK and TOM-1 cells while in Reh cells
Aplidin induced an irreversible growth inhibitory effect, but only
at 20nM. To assess the sensitivity of the leukaemic cell lines to
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Figure 1 Effect of 1h (A) or 15, 60min 24h (B) Aplidin exposure on
cell growth evaluated at different time intervals after treatment and drug-
washout on ALL-PO, Reh, ALL/MIK and TOM-1. Each point is the mean of
three replicates; bars respresent the standard deviation.
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20nM Aplidin for 15min, 1 or 24h. As shown in Figure 1B the
cytotoxicity against ALL-PO, Reh and TOM-1 cells was similar
regardless of the incubation times. In contrast, ALL/MIK cells with
15min of exposure to Aplidin survived longer than ALL/MIK cells
after more prolonged treatments. Yet, an optimal effect was
achieved by 1h since similar effects were also seen at 24h
(Figure 1B).
The lack of increased cytotoxicity of Aplidin beyond 1h
compared to a short exposure time might have been due to a
rapid decomposition of the peptide under cell culture conditions.
However, this was not found to be the case. After 24h incubation
of Aplidin in medium at 371C, 80% of the drug was detected as
unchanged by HPLC–MS (data not shown).
Cell cycle perturbations induced on ALL cell lines
Figure 2 shows the effects on the cell cycle phase distribution
caused by 1h exposure with different concentrations of Aplidin in
the different leukaemic cell lines evaluated at different time
intervals after drug-washout. We found that in all the ALL cell lines
Aplidin caused a block of the cells in the G1 phase of the cell cycle.
In Reh, ALL/MIK and TOM-1 cells Aplidin induced also a G2
block.
To better characterise the cell cycle phase perturbation induced by
Aplidin the biparametric BrdU/DNA flow cytometric analysis were
performed at different time intervals after drug-washout. Figure 3
reports, as an example, the DNA histograms of BrdU-negative and
BrdU-positive cells obtained in Reh cells. Aplidin was found to delay
those cells that were in the G1 phase (BrdU-negative cell population)
during drug treatment from entering S phase. At 40h after drug-
washout, the BrdU-negative cells were accumulated in G1 and in G2.
The cells that were in S phase (BrdU-positive cells) during Aplidin
treatment progressed throughout this phase of the cell cycle more
slowly than control cells. At 18h and UP 40h after; drug-washout,
the BrdU-positive cells were accumulated in G1 and in G2.
Aplidin-induced apoptosis on ALL cell lines
It has been reported that Aplidin acts in vitro by inducing
apoptosis on different cells lines (Grubb et al, 1995; Erba et al,
2002). Aplidin induced apoptosis in all the cell lines used, as clearly
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Figure 2 Cell cycle phase perturbations induced on (A) ALL-PO, (B) Reh, (C) ALL/MIK and (D) TOM-1 cells treated for 1h with 0, 5, 10 or 20nM
Aplidin. Monoparametric DNA flow cytometric analysis were performed at different time intervals after drug-washout.
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Dapi staining (data not shown). The level of apoptotic cells was
different between the four cell lines as shown in Figure 4A, which
shows an example of the TdT-dUTP flow cytometry analysis, and
in Figure 4B, where the percentages of the fraction of apoptotic
cells found at different times after drug-washout are reported. In
Reh cells, Aplidin induced apoptosis only at the concentration of
20nM. In ALL-PO, ALL/MIK and TOM-1 the amount of apoptotic
cells increased dramatically when the cells were exposed to 10 or
20nM Aplidin. In All-PO cells at 72h after drug-washout 80% of
the cells treated with 20nM of Aplidin were apoptotic. As
previously reported on other cell type (Garcia-Fernandez et al,
2002), Aplidin was found to induce apoptosis in a caspase-3-
dependent manner (Figure 5).
Modulation of VEGF secretion by Aplidin on ALL cell lines
It has been reported by our group that Aplidin causes a strong
block of VEGF secretion in Molt-4 cells with a subsequent
downregulation of the transcription of VEGF and of its receptor
VEGFR1 (Broggini et al, 2003). To test the hypothesis that Aplidin
could exert its activity in ALL cell lines by inhibiting the VEGF/
VEGFR-1 autocrine loop, we used an RNAse protection assay in
each cell line. As shown in Figure 6, all the cell lines used
expressed, at different levels, the VEGF mRNA and its receptors.
ALL/MIK and Reh expressed the flt-1 receptor, ALL-PO only the
flt-4 receptor while TOM-1 expressed both of them. Data reported
in Figure 7 show that after different times from drug-washout,
Aplidin downregulated the level expression of VEGF mRNA in
ALL-PO cells. When tested in the other cell lines this observation
was not further confirmed as shown in Figure 8. By using ELISA
assay, we tested the level of VEGF secretion in the four leukaemia
cell lines used and found that only ALL-PO secrete detectable
amounts of the growth factor. Therefore, we evaluated whether a
block in VEGF secretion in ALL-PO cells occurs as previously seen
in Molt-4 cells (Broggini et al, 2003). We treated ALL-PO cells with
20nM Aplidin for 1h and tested the medium of the cells by means
of an ELISA assay used to measure VEGF-A levels of secretion at 0,
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Figure 4 (A) Detection of apoptosis in ALL cells by TdT-dUTP flow cytometric analysis. Cells were treated with different concentrations of Aplidin and
the biparametric FSC/TdT-dUTP analysis were performed after 72h after drug-washout. (B) Percentage of apoptotic cells evaluated by TdT-dUTP flow
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s6 and 24h after drug-washout. As depicted in Figure 9 Aplidin was
able to substantially abolish VEGF secretion in the medium at 6
and 24h after drug-washout.
Cytotoxicity and apoptosis induced by Aplidin on primary
ALL cells
To assess the cytotoxic effect of Aplidin on fresh leukaemia cells
obtained directly from patients affected by BCP-ALL, a stroma-
supported immunocytometric assay was used. Previous studies
have shown that, under these culture conditions, phenotypic and
karyotype features of leukaemia cells are maintained even after
several months of culture.
Table 1 shows the clinical features of the ALL patients at the
time when the cells were derived. In nine out of 14 cases (nos. 1–9)
the leukaemia cells were collected at the time of diagnosis, while in
the other five cases (nos. 10–14), at the time of relapse. Among the
14 samples of ALL studied, the number of cells recovered after 7
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Figure 5 Detection of active caspase-3 in ALL cells by flow cytometric
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Figure 6 Autoradiography of a typical RNAse protection assay on the
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cells were used as an internal control.
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sdays of stromal-supported culture ranged from 38 to 210%
(median 83%) of those originally seeded.
It is known that changes in forward/side light-scatter para-
meters, consisting in a reduction in forward scatter, indicating a
reduction in cell size, and an increase in side scatter, indicating an
increase in cell granularity, are frequently associated with
apoptosis. As detected on leukaemic cell lines Aplidin induced
changes in the light-scattering properties by using flow cytometry
forward/side light-scatter analysis on ALL cells too, suggesting an
induction of apoptosis (Figure 10 shows a representative case).
A ss h o w ni nT a b l e2 ,t h ec y t o t o x i ce f f e c to fA p l i d i no nB C P - A L L
cells was dose dependent. Aplidin at the concentration of 5nM was
strongly cytotoxic in all cases. The percentage of cell death ranged
from 74 to 100% (median 97%). At the concentration of 0.5nM Aplidin
cell killing effect was not detectable in three cases (nos. 7, 8 and 9),
while in the remaining 11 cases it ranged from nine to 99% (median
49%). Aplidin at 0.05nM induced cell death in seven out of 13 cases
(nos. 1–5 12 and 13) with a range from nine to 79% (median 20%). At
0.005nM substantial cytotoxicity (47% compared to control cells) was
observed only in one case (no. 13). Interestingly, the same level of cell
kill (median 97%) was obtained with 5nM Aplidin in cells taken either
at the time of diagnosis (nos. 1–9) or at relapse (nos. 10–14).
The cytotoxicity of Aplidin extended to sample nos. 7 and 9,
each of which carries adverse genetic features such as t(9;22) and
t(4;11), respectively.
To investigate whether Aplidin cytotoxicity represents a direct
effect on leukaemic cells or an indirect effect mediated by damage
of the stroma layers, we incubated the stroma layers for 7 days with
different Aplidin concentrations ranging from 0.005 to 5nM. Then
the cells were washed and seeded with leukaemic lymphoblasts in
drug-free medium for 7 days. We found that the morphology and
cell confluence were not affected by Aplidin treatment. In four out
of five cases the percentage cell recovery obtained after 5nM
Aplidin exposure was between 78 and 92%. Only in one case did
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Figure 7 Autoradiography of RNAse protection assay on ALL-PO cells
treated with 20nM Aplidin performed at different time intervals after drug-
washout.
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Figure 8 Vascular endothelial growth factor mRNA levels in human
leukaemic ALL-PO, ALL-MIK and Reh cell lines treated with 20nM Aplidin
and performed at different time intervals after drug-washout. Data have
been obtained by densitometric analysis and expressend as % of control
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Figure 9 Vascular endothelial growth factor-A concentration in the
medium of ALL-PO cells treated for 1h with 20nM Aplidin and evaluated
at 0, 6 and 24h after drug-washout. The values express the % of VEGF
concentration in the medium of treated cells with regard to control cells.
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sthe ability of stromal cells to support leukaemia cell survival after
Aplidin treatment not occur (data not shown).
DISCUSSION
This study shows that Aplidin is a potent antileukaemic agent
against human lymphoblastic leukaemia cell lines, as well as fresh
leukaemia cells derived directly from patients with childhood BCP-
ALL. We found that on Philadelphia chromosome-positive TOM-1
and ALL/MIK with t(9;22), on ALL-PO with t(4;11) and on Reh
t(12;21) cell lines, Aplidin induced a strong growth inhibition
effect at nanomolar concentrations, the IC50 ranging from 5 to
20nM.
The present study also shows that Aplidin is a strong inducer of
apoptosis, a finding in keeping with previous data obtained on
another human leukaemia Molt-4 cell line (Erba et al, 2002;
Broggini et al, 2003). In all the cell lines investigated, the Aplidin-
induced cell death was clearly related to the induction of apoptosis,
even if in Reh cells the apoptosis was found only when the cells
were exposed to high concentrations of Aplidin. ALL/MIK and
TOM-1 cells express wt p53, whereas the other a mutated p53 (M
Broggini, personal communication), thus indicating that Aplidin
can induce apoptosis in a p53-independent manner.
We have recently reported that in Molt-4 cells Aplidin causes an
inhibition of VEGF secretion and a downregulation of flt-1
(Broggini et al, 2003). The apoptosis induced by Aplidin in
Molt-4 cell could be observed also by exposing the leukaemic cells
to anti-VEGF antisense oligonucleotide (Gerber et al, 1998; Nor
et al, 1999; Broggini et al, 2001, 2003). In these cells, the addition of
VEGF could antagonise the apoptotic process induced by Aplidin.
These data suggested that a potential mechanism of cytotoxicity of
Aplidin was related to the blocking of an autocrine loop relevant
for cell growth and survival. In the present study, however, we
could not confirm this finding. In only one cell line, that is ALL-PO
cells, we found evidence of the same phenomenon previously seen
in Molt-4 cells. Since the sensitivity of ALL-PO cells to Aplidin is
comparable to that observed for other ALL cell lines such as Reh,
ALL/MIK and TOM-1, in which Aplidin was not inducing any
effect on VEGF secretion, it should be concluded that Aplidin
cytotoxicity against ALL cells is not related to VEGF inhibition. It
may be speculated, however, that in the cell lines in which no block
of VEGF loop was observed, Aplidin cytotoxicity is mediated by
the inhibition of other growth factors. The evidence that Aplidin
induces changes in the expression of genes involved in different
cellular pathways (Marchini et al, 2002) is in line with this
hypothesis. However, these aspects require to be further investi-
gated.
The available data on the effects of didemnins on the cell cycle
consistently indicate that these compounds cause a block of the
cells in G1 (Crampton et al, 1984; Erba et al, 2002). It has been
recently reported that in Molt-4 Aplidin mainly induces a G1 block,
but a more sophisticated analysis revealed that the drug induced a
G2 block too (Erba et al, 2002). In particular, by using a simulation
program (Montalenti et al, 1998) suitable to describe drug-induced
cell cycle block, delay, repair and death effects, it became apparent
that a G2 blockade also occurs in Molt-4 cells exposed to Aplidin.
In the present study we can confirm that in addition to a G1 arrest
aG 2 blockade was induced by Aplidin in ALL cell lines.
Aplidin was found to induce a strong cytotoxicity in patient-
derived leukaemia cells evidenced in a stroma-supported im-
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Figure 10 Example of light-scatter dot-plot analysis of blast cells growing
on stroma feeder layer evaluated by flow cytometry. Forward and side
scatter analysis were evaluated at the beginning of culture (A), after 7 days
of culture (B, control cells) and after 7 days with 5nM Aplidin (C, treated
cells).
Table 2 Stroma-supported immuno cytometric assay – % cell death
after 7 days Aplidin exposure
Aplidin (nM)
Patient no 0.005nM 0.05nM 0.05nM 5n M
1N T 1 2 2 2 9 6
2 NT 79 79 100
31 4 2 0 4 0 9 9
4 16 36 60 100
5 12 19 46 100
6 o1 o19 9 6
7 o1 o1 o17 4
8 o1 o1 o19 7
9 o1 o1 o19 0
10
a 31 3 35 82
11
a o1 1 49 98
12
a 10 9 99 88
13
a 47 33 55 97
14
a o1N D5 0 9 7
a¼relapse. ND¼not determined.
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smunocytometric assay. This system has been successfully used to
investigate the antileukaemic activity of different compounds, such
as 2-chloro-2-deoxyadenosine (Kumagai et al, 1994), Interferon-a
(Manabe et al, 1993), Cyclosporin A (Ito et al, 1998), Taxol and
Taxotere (Consolini et al, 1998), Vincristine, Teniposide and Ara C
(Campana et al, 1993, 1999). Aplidin at 5nM caused a dramatic cell
death (median 97%) in all the 14 cases studied. At 0.5nM cell death
was still present in 11 out of 14 cases (median 49%). Although in
some cases there might be discrepancies between the in vitro
cytotoxic concentration and the active anticancer drug plasma
levels, note that the Aplidin concentrations used are pharmaco-
logically reasonable as Aplidin concentrations above 20nM are
achievable for several hours in the plasma of patients receiving the
drug given as 24h in a range doses much lower than the maximum
tolerated dose of 6000mgm
 2 (Zucchetti, personal communica-
tion).
Cells from two children with genetic abnormalities such as
t(9;22) and t(4;11) translocation, which are associated with an
inferior treatment outcome, were sensitive to Aplidin to the same
extent as that observed in other BCP-ALL cases. Likewise, the cell
lines with t(9;22) (ALL/MIK and TOM-1) or t(4;11) (ALL-PO) were
strongly sensitive to Aplidin at similar concentrations.
In relapsed ALL cases, Aplidin exerted a strong cell killing effect
(97%) in all five primary cells indicating that Aplidin is a candidate
antileukaemic agent in patients with ALL that are nonresponsive to
standard chemotherapeutic agents.
The data obtained with ALL cell lines and on Molt-4 cells (Erba
et al, 2002) clearly indicate a direct antileukaemic activity of
Aplidin. However, in the stroma-supported cultures of BCP-ALL
cells derived from patients, the Aplidin-induced apoptosis could be
due to a toxic effect to stroma cells (Campana et al, 1993; Consolini
et al, 1998; Ito et al, 1998). We did not find a decrease in the
capacity of stroma pretreated with Aplidin, to support ALL cell
viability. Recently (Albella et al, 2002), similar data have been
reported on human bone haematopoietic progenitors treated by
Aplidin. At concentrations similar to those used in this study
Aplidin did not induce growth inhibition in the tested haemato-
poietic progenitors by using clonogenic assay. It must be taken
into account that stroma is characterised by the presence of
different cell types including endothelial, reticulo cells, macro-
phages, fibroblast and adipocytes. As the stroma layers used in this
study were derived from different patients, the reduced survival of
ALL cells found in one case after exposure to 5nM Aplidin, could
be related to biological variability in the susceptibility of the
different cell types present in the stroma layer.
Although the treatment outcome of children affected by ALL
showed marked improvements in the last decade, in one-third of
the children, ALL is fatal. Identification of new antileukaemia
agents is essential for improving the survival of patients with high-
risk or refractory leukaemia. Clinical Phase I and II studies of
Aplidin have shown antitumour activity in patients with neuroen-
docrine tumours and medullary thyroid carcinomas (Raymond
et al, 2000; Armand et al, 2001; Ciruelos Gil et al, 2002). Since at
the recommended doses for phase II studiesAplidin plasma levels
are maintained for many hours in the range of 10–100nM
(Zucchetti, personal communication; Maroun et al, 2001, accord-
ing to the results presented in this study it seems realistic to
assume the drug has a potential for therapy of ALL patients
resistant to or relapsing from the available chemotherapies.
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